Projects

  • Hypoxia-induced metabolic shifts in acute myeloid leukemia (AML) PI: Nina Kurrle

  • Effect of the bone marrow microenvironment on the cellular behavior, proteome and metabolome in AML PI: Nina Kurrle, Frank Schnütgen

  • Effect of the bone marrow microenvironment on the cellular behavior, proteome and metabolome in multiple myeloma PI: Ivana von Metzler, Nina Kurrle

  • Dissecting the ROS-regulatory mechanisms of Sestrins in mTORC1 suppression PI: Nina Kurrle

  • Exploring Template-free CRISPR/Cas9 Genome Editing as a Novel Strategy for Personalized Gene Therapy of Monogenic Blood Disorders PI: Frank Schnütgen

    A significant fraction of inherited monogenic disorders are caused by patient-specific mutations dispersed over the entire locus of the affected gene. Correcting these mutations by introducing healthy gene copies into the genome of the diseased cells by retroviral vectors proved successful in several clinical trials, but complications arose including gene silencing and activation of cancer causing genes. To circumvent these problems, we are developing a template-free CRISPR/Cas9 based genome editing approach for the in situ correction of point mutations causing Chronic Granulomatous Disease (X-CGD) and Hemophilia A, which are inherited monogenic disorders. For this, we will generate human hematopoietic and hepatic sinusoidal endothelial cell lines expressing single copy CYBB and FVIII genes, respectively, harboring patient specific mutations and use these cell lines for gene correcting CRISPR/Cas9 based, lentiviral vectors. This project seeks to provide proof of concept for personalized gene therapy.

  • Development of a haploid genetic screen for the characterization of signaling pathways mediating drug resistance in leukemia. PI: Frank Schnütgen

  • Deciphering the Metabolism of Haematological Cancers PI: Nina Kurrle

  • Investigation of the histone demethylase LSD1/KDM1A as a therapeutic target in AML PI: Tobias Berg

  • Role of JMJD3 in B cell development and lymphoid neoplasia PI: Tobias Berg